List clinical trials by disease
The results of your search are listed below. To view the details of a trial or study, click on the link. Or start a new search.
Searched for: Sarcoma. 10 results shown below.
Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
[Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma]
NY-ESO-1-specific T Cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy
[Complete title: A pilot trial of NY-ESO-1-specific T cells in patients with metastatic NY-ESO-1-expressing sarcomas receiving palliative radiation]
Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
[Complete title: The Effect of Antiangiogenic Therapy with Pazopanib Prior to Preoperative Chemotherapy for Subjects with Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging]
TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Metastatic Sarcoma
[Complete title: A Pilot Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma]
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
[Complete title: A Study To Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma using Autologous NY-ESO-1 Specific CD8+ T Cells with Cyclophosphamide Pre-Conditioning but Without the Use of IL-2]
Treatment of High Risk Renal Tumors; A Groupwide Phase II Study.
Doug Hawkins, MD
Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
Doug Hawkins, MD
A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Julie Park, MD
A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
[Complete title: A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment]
A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma
[Complete title: An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue Sarcoma]
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.